Back to top
more

Bausch Health (BHC)

(Delayed Data from NYSE)

$8.53 USD

8.53
3,432,592

+0.17 (2.03%)

Updated Jul 1, 2022 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.75%
2Buy18.15%
3Hold9.70%
4Sell5.35%
5Strong Sell2.45%
S&P50010.91%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (146 out of 251)

Industry: Medical - Generic Drugs

Trades from $1

Zacks News

Bausch (BHC) Suspends IPO Plans for Solta Medical

Bausch (BHC) suspends its plans for the initial public offering of its Solta Medical business in light of the challenging market conditions and other factors.

Why Is Bausch (BHC) Down 11.2% Since Last Earnings Report?

Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Implied Volatility Surging for Bausch (BHC) Stock Options

Investors need to pay close attention to Bausch (BHC) stock based on the movements in the options market lately.

New Strong Sell Stocks for May 19th

ASX, CNMD, and BHC have been added to the Zacks Rank #5 (Strong Sell) List on May 19, 2022.

Bausch (BHC) Q1 Earnings and Revenues Miss, Stock Down

Bausch (BHC) misses on earnings and sales in the first quarter due to incremental macro pressures and a challenging supply chain environment.

Kanishka Das headshot

Drug/Biotech Stocks' Q1 Earnings on May 10: EXEL, BHC & More

Let's look at the five biotech/drug companies that are slated to release quarterly results on May 10.

BridgeBio Pharma (BBIO) Reports Q1 Loss, Misses Revenue Estimates

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -5.31% and 80.59%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Bausch Health (BHC) Stock Sinks As Market Gains: What You Should Know

Bausch Health (BHC) closed the most recent trading day at $18.85, moving -0.84% from the previous trading session.

Indrajit Bandyopadhyay headshot

3 Generic Drug Stocks to Watch Amid Continued Pricing Pressure

The impact of COVID-19 and continued pricing pressure on the Zacks Medical-Generic Drugs industry remains. New product launches may provide some respite for BHC, AMPH and SLGL.

Bausch Health (BHC) Stock Sinks As Market Gains: What You Should Know

Bausch Health (BHC) closed at $21.48 in the latest trading session, marking a -0.88% move from the prior day.

Aerie (AERI) Expands Market Presence Despite Stiff Competition

Aerie (AERI) is progressing well with the development of its ophthalmology pipeline. Its partnership with Santen Pharmaceuticals allows it to expand the presence of its drugs outside the United States.

Bausch Health (BHC) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Bausch Health (BHC) closed at $23.23, marking a -1.69% move from the previous day.

Bausch Health (BHC) Stock Moves -0.56%: What You Should Know

In the latest trading session, Bausch Health (BHC) closed at $23.17, marking a -0.56% move from the previous day.

Bausch (BHC) Up 1% Since Last Earnings Report: Can It Continue?

Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Bausch Health (BHC) Outpaces Stock Market Gains: What You Should Know

Bausch Health (BHC) closed the most recent trading day at $24.05, moving +1.69% from the previous trading session.

Bausch Health (BHC) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Bausch Health (BHC) closed at $21.97, marking a -1.08% move from the previous day.

Bausch Health (BHC) Dips More Than Broader Markets: What You Should Know

Bausch Health (BHC) closed at $22.56 in the latest trading session, marking a -0.84% move from the prior day.

Bausch's (BHC) Q4 Earnings Beat Estimates, Revenues Miss

Bausch (BHC) beats on earnings but misses on sales in the fourth quarter. The outlook for 2022 is disappointing.

Bausch Health (BHC) Beats Q4 Earnings Estimates

Bausch (BHC) delivered earnings and revenue surprises of 17.59% and 0.45%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Drug/Biotech Stocks' Q4 Earnings on Feb 23: BMRN, BHC & More

Let us take a look at five drug/biotech companies, namely, BMRN, CLVS, TBPH, BHC and GBT, which are due to release their quarterly results on Feb 23.

What's in the Cards for Bausch Health (BHC) Q4 Earnings?

An update on the IPO of Bausch+Lomb and regular top-line and bottom-line numbers will grab investors' attention when BHC reports Q4 results.

Bausch Health (BHC) Dips More Than Broader Markets: What You Should Know

Bausch Health (BHC) closed at $24.74 in the latest trading session, marking a -1.55% move from the prior day.

Bausch Health (BHC) Outpaces Stock Market Gains: What You Should Know

Bausch Health (BHC) closed at $24.78 in the latest trading session, marking a +1.6% move from the prior day.

Bausch Health (BHC) Dips More Than Broader Markets: What You Should Know

Bausch Health (BHC) closed at $24.39 in the latest trading session, marking a -0.53% move from the prior day.

Bausch Health (BHC) Gains But Lags Market: What You Should Know

In the latest trading session, Bausch Health (BHC) closed at $24.57, marking a +1.78% move from the previous day.